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Background. Repetitive transcranial magnetic stimulation (rTMS) has shown promising effects in the treatment of chronic
subjective tinnitus. However, little is known aboutmaintenance treatment in order to achieve long-lasting improvements.Objective.
This study addresses the questions whether the repeated application of rTMS treatment can contribute to the maintenance or
enhancement of treatment effects and if so in which cases repetitive treatment courses are beneficial. Methods. 55 patients with
chronic tinnitus were treated with two rTMS treatment courses with ten treatment sessions each.Themean intertreatment interval
was 20.65 ± 18.56 months. Tinnitus severity was assessed before and after each treatment course. Results. Both treatments were well
tolerated and caused significant improvement of tinnitus severity. The main predictor for the outcome of the second treatment was
the development of tinnitus distress in the phase between both treatment courses: the more patients worsened in this interval, the
more they improved during the second treatment course. Conclusion. Repeated application of rTMS seems to be useful in tinnitus
management and should preferentially be offered to patients who experience a worsening of their tinnitus during the intertreatment
interval, irrespective of their response to the first treatment course.
1. Introduction
In the past decade, an increasing number of studies have
examined the effectiveness of repetitive transcranial mag-
netic stimulation (rTMS) as a treatment option for chronic
subjective tinnitus (for a review, see [1, 2]). Generally, the
reduction of the tinnitus percept and distress after five to ten
sessions of rTMS is reported to be mixed with respect to both
duration and extent of improvement. While some studies
indicate that the improvement vanishes after twoweeks [3, 4],
other studies observed rather long-lasting effects up to 4 years
[5–7]. Likewise, while some patients report no or only little
benefit, others improve a lot due to rTMS treatment. Besides
this heterogeneous clinical improvement, the actual impact
of rTMS treatment on the morphology of the brain seems to
be of transient nature [8]. In any case, tinnitus is a chronic
condition and the question arises what might be the next
therapeutic step either if a patient still feels burdened by his
tinnitus after a treatment attempt with rTMS or if the benefit
of the treatment wanes over time. In these cases the repeated
application of rTMS treatment might be useful. The idea
to use repeated stimulation courses to maintain treatment
effects is known from electroconvulsive therapy (ECT) of
major depression, where immediate treatment effects are of
temporary nature as well and where relapses of depressive
symptoms are managed successfully by periodic repetition
of ECT [9, 10]. Recently, it has even been debated whether
rTMS could be used as maintenance method after an initial
ECT therapy [11, 12]. Also, there already is some evidence
for repeated rTMS treatments from studies examining the
benefit of rTMS in patients with psychiatric or neurological
disorders (for an overview, see [13]). In patients suffering
from depression who had responded to an initial rTMS treat-
ment, both the repetition of the whole treatment schedule
after relapse of depressive symptoms [14, 15] and intensive
monthly maintenance sessions to prevent the occurrence of
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a relapse [16, 17] have been shown to be effective. Therefore,
it is reasonable to assume that some kind of repeated rTMS
treatmentmight also be useful in tinnitusmanagement. Up to
now there is little information on the effect of repeated rTMS
therapies in tinnitus patients. Some case reports, small case
series, and one study suggest that rTMS “booster” sessions
might be effective as maintenance treatment for treatment
responders and might even result in more pronounced
tinnitus reduction than the initial treatment [13, 18–20].
Furthermore, maintenance treatment has been found to be
well tolerated [13]. However, the sample sizes of those studies
were small and only initial treatment responders were con-
sidered for repeated treatment. It remains unclear whether
patients who had not responded to the initial treatment are
“rTMS nonresponders” per se or whether they might benefit
from rTMS treatment at some other point in time. As the
effect of rTMS is known to be state-dependent [21], it is
quite conceivable that a nonresponder might benefit from a
second treatment course indeed. By presenting data of a large
sample of patients who underwent two complete treatment
courses of 10 days of rTMS, including both responders and
nonresponders to the initial treatment, the current study tries
to answer the questionswhether (a) repeated courses of rTMS
are safe, (b) whether they can contribute to the maintenance
of treatment effects or may even enhance treatment response,
and (c) in which cases a second treatment course might be
beneficial.
2. Materials and Methods
Data from 55 patients (43 men, 12 women) with chronic
subjective tinnitus were included in the analyses. Inclusion
criteria were age over 18 years and chronic subjective tinnitus
for at least 6 months. Exclusion criteria were treatable cause
of tinnitus and all contraindications for rTMS treatment
(pregnancy, epilepsy, cardiac pacemaker, head injury, and
metal objects in or around the body which cannot be
removed). Demographical data and clinical characteristics
of the sample are given in Table 1. All patients underwent
two complete treatment courses with each course consisting
of ten sessions of rTMS on ten consecutive working days.
Treatment was performed at the Tinnitus Center at the
University of Regensburg, Germany. All patients provided
written informed consent before both treatment courses.
The first treatment course was done either in the context
of a controlled clinical trial, open-label feasibility studies,
or as compassionate use treatment. Part of the data of the
first treatment course was therefore already published in
the context of the respective study [22–28]. After the first
treatment course, patients were informed about the option
to repeat rTMS treatment but no appointments were made.
This means that the patients decided for themselves if and
when they wanted to repeat rTMS treatment. This could be
after a worsening of symptoms, because patients hoped for
an enhancement of their improvement or because former
nonresponders wanted to retry rTMS treatment. The mean
interval between both treatment courses was 20.65 ± 18.56
months.
Table 1: Demographical data and clinical characteristics of the
sample.
Gender 43 males, 12 females
Age (years) 52.49 ± 11.42
Tinnitus duration (years)* 7.94 ± 7.15
Tinnitus laterality
5 right
8 left
12 both ears worse left
8 both ears worse right
19 both ears equally
3 inside the head
Intertreatment interval (months) 20.65 ± 18.56
Identical treatment protocol for both
treatment courses 30 yes, 25 no
TQ difference 1 −4.45 ± 10.13
TQ difference 2 −4.47 ± 8.23
TQ difference intertreatment interval 4.91 ± 14.42
Data are given as mean ± standard deviation.
*Before starting of first treatment course.
As data was collected over a long period of time (between
2003 and 2014), different treatment protocols were used
(see Table 2). Each protocol contained low-frequency (1Hz)
rTMS of the left temporal or temporoparietal cortex with
2000 or 4000 stimuli per day. In the multisite protocols,
additional high-frequency stimulation of the left dorsolateral
prefrontal (20Hz) or medial frontal cortex (10Hz) or low-
frequency stimulation of the right temporoparietal cortex
(1Hz) was involved. The high-frequency stimulation was
always done first, followed by the low-frequency part. All
treatment protocols were used in the context of clinical trials
which had been approved by the local ethics committee.
Localization of the stimulated areas was either done with
a neuronavigational system or by using a standard proce-
dure based on the 10–20 system [29–35]. Stimulation was
applied with a Medtronic system with a classical figure-8-
coil or, for the medial frontal stimulation, a double-cone-
coil (Medtronic, Minneapolis, MN, USA). During treatment,
the coil was held by a mechanical arm and the patients were
seated comfortably in a reclining chair. Stimulation intensity
was set at 110% of the individual resting motor threshold
(RMT) for the figure-8-coil and 100% RMT for the double-
cone-coil. RMTwas defined as theminimal intensity at which
motor evoked potentials were 50𝜇V in amplitude in the right
abductor digiti minimi muscle for five out of ten stimulations
[36]. Tinnitus distress was assessed before (baseline) and after
(day 12) each treatment course using the German version of
the tinnitus questionnaire (TQ, [37]).
IBM SPSS Statistics 22 (IBM Corporation, Armonk,
NY) was used for data analyses. To test for changes in
tinnitus severity due to rTMS treatment, paired 𝑡-tests were
performed for the first and the second treatment course
separately. For all further analyses, the difference of the TQ
scores between baseline and day 12 was calculated with neg-
ative values indicating an improvement in tinnitus severity.
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Table 2: Treatment protocols used in the first and second treatment courses.
Number of patients treated
1st treatment 2nd treatment
Left temporal rTMS, 1Hz, 2000 stimuli/day 19 10
Left temporal rTMS, 1Hz, 4000 stimuli/day 4 —
Left temporal (1 Hz) plus left frontal (20Hz) rTMS, 2000 stimuli/day 2 —
Left temporal (1 Hz) plus left frontal (20Hz) rTMS, 4000 stimuli/day 22 31
Left and right temporoparietal (1 Hz) plus left frontal (20Hz) rTMS, 4000 stimuli/day 5 13
Left temporoparietal (1 Hz) plus medial frontal (10Hz), 4000 stimuli/day 3 1
Below, those difference scores are named “TQ difference 1”
for the first treatment course and “TQ difference 2” for the
second treatment course. Furthermore, the TQ difference of
the intertreatment interval (ITI) was calculated to represent
the development of tinnitus severity in the phase between
both treatment courses (“TQ difference ITI”; baseline of the
second treatment minus day 12 of the first treatment). To
assess which patients benefit from a second treatment course,
the following parameters were considered as possible predic-
tors for TQ difference 2: TQ difference 1, the baseline score of
the second treatment course, TQ difference ITI, the duration
of the intertreatment interval (in months), and the change
of treatment protocol from treatment one to treatment two
(i.e., if the same protocol was used for both treatment courses,
dummy coded). In a first step, all of those parameters were
analysed with respect to their relation to TQ difference 2
using product-moment correlations for metric variables and
a 𝑡-test for the discrete variable. All variables with significant
influence on TQ difference 2 were entered as regressors into
a multiple linear regression analysis (simultaneous model)
where TQ difference 2 served as dependent variable. This
was done in order to examine which regressors exert most
influence if the other regressors are controlled for and to find
out whether there are important interaction effects. Finally,
in order to find out whether one of the different rTMS
protocols was more effective than the others, analyses of
variance (ANOVAs) were calculated. The TQ differences of
the first or second treatment course were used as dependent
variables and the rTMS protocols were used as independent
variables (six protocols in the first treatment course, four
protocols in the second treatment course; see Table 2). The
level of significance was set at 0.05.
3. Results
All patients tolerated both treatment courses without any
severe adverse effects. All treatments were completed as
planned. Paired 𝑡-tests revealed that both the first and
the second treatment course significantly reduced tinnitus
severity asmeasured by the TQ (first treatment course 𝑡(54) =
3.26, 𝑝 = 0.002; second treatment course 𝑡(54) = 4.033, 𝑝 <
0.001). Please see Table 1 for mean and standard deviation
of the TQ differences. Figure 1 shows the development of
the TQ score over time. The 𝑡-test which was done to find
out whether a change of treatment protocol from treatment
one to treatment two had an influence on the outcome of
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Figure 1: Change of theTQ score over time (mean± standard error).
The intertreatment interval is depicted as dashed line.
the second treatment revealed no significant effect (𝑡(53) =
−0.89, 𝑝 = 0.376). The product-moment correlations with
TQ difference 2 were not significant for the duration of the
intertreatment interval (𝑟 = −0.167, 𝑝 = 0.223) and the
baseline score of the second treatment course (𝑟 = −0.128,
𝑝 = 0.351). In contrast, the correlations were significant for
TQ difference 1 (𝑟 = 0.282, 𝑝 = 0.037) and TQ difference ITI
(𝑟 = −0.475, 𝑝 < 0.001). Therefore, the latter two variables
were entered as regressors in the linear regression analysis.
Additionally, an interaction term between both variables was
created by multiplying the centred variables. This term was
also entered into the regression analysis. The TQ difference
of the intertreatment interval significantly predicted the
outcome of the second treatment course (𝛽 = −0.452, 𝑡 =
−3.12, and 𝑝 = 0.003) while both TQ difference 1 (𝛽 = 0.041,
𝑡 = 0.28, and 𝑝 = 0.780) and the interaction term (𝛽 =
−0.013, 𝑡 = −0.11, and 𝑝 = 0.915) were no significant
predictors.Thus, TQdifference 1 loses its significant influence
on TQ difference 2 if TQ difference ITI is controlled for.
The overall model fit was 𝑅2 = 0.227, 𝐹(3, 51) = 5.00,
and 𝑝 = 0.004. The scatter plot in Figure 2 shows the
relation between TQ difference 2 and TQ difference ITI.
The ANOVAs comparing the TQ differences obtained by
the different treatment protocols turned out nonsignificant
(𝐹(5, 49) = 0.37; 𝑝 = 0.869 for the first treatment course;
𝐹(3, 51) = 1.48, 𝑝 = 0.231 for the second treatment
course) indicating that none of the protocols was significantly
superior (see Figure 3).
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4. Discussion
This is the first study to examine repeated rTMS treatment
courses in a rather large sample of tinnitus patients where
responders as well as nonresponders of the initial treatment
course were included. Both the first and the second treatment
were well tolerated and led to a significant reduction of
tinnitus severity. This finding confirms previous findings
from smaller samples [13, 18, 19] and further supports the
usefulness of repeated rTMS treatment for the management
of chronic disorders like tinnitus. As can be seen in Figure 1,
the average TQ scores decreased after the first treatment,
increased in the intertreatment interval, and improved again
during the second treatment course. These group data sug-
gest that the beneficial effect of the first rTMS treatment
vanishes over time during the intertreatment interval but
can be renewed by repeated rTMS. The regression analysis
provides additional insights. It reveals that TQ difference 2 is
significantly related to bothTQdifference 1 andTQdifference
ITI. However, TQ difference 1 loses its significant influence
if TQ difference ITI is controlled for. This means that the
development of the TQ score during the intertreatment
interval is a good predictor for the outcome of the second
treatment course and that the outcome of the first treatment
course provides hardly any additional predictive information.
Consequently, a second treatment attempt might be most
promising for patients who worsen between both treatment
courses (see Figure 2), irrespective of the success of the
first treatment. Interestingly enough, the baseline value of
the second treatment is not significantly correlated with
TQ difference 2. Thus, patients who worsen between both
treatments do not have better outcomes to a second treatment
course simply because they have higher baseline values. It
was already observed previously that patients whose TQ
score had increased in the period before initiation of rTMS
benefited more than patients with prior improvement of
tinnitus severity [27, 38]. One possible explanation for this
effect is that the pretreatment changes in tinnitus severity
might reflect a particular neurobiological condition of the
brain which makes a response to rTMS more or less likely.
As is known from former studies [21, 39, 40] the effect
of rTMS depends on the state our brain is in when it is
stimulated. Maybe, a worsening of tinnitus is accompanied
by a neuronal activation pattern which makes the tinnitus
brainmore receptible to rTMS than a brain which is currently
experiencing no change or improvement of tinnitus severity.
This would also explain why the baseline score of the second
treatment course, the duration of the intertreatment interval,
and the change of the stimulation protocol did not correlate
significantly with the outcome of the second treatment
course—the baseline score alone tells us little about the
process the brain is currently in—nor does the duration of
the intertreatment interval. And a change of the stimulation
protocol might only be promising if our brain is in a state
susceptible to rTMS intervention and if the new protocol
fits this state. This is only speculation, of course, and future
controlled studies are needed to shed more light on the
relation between the activational state of the tinnitus brain
and its responsiveness to rTMS and to find out whether
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Figure 2: Point diagram showing the relation between the outcome
of the second treatment course and the TQ difference of the
intertreatment interval.
there are clinical markers (like the TQ difference of the
intertreatment interval) which reflect such an advantageous
state reliably.
With respect to the repetition of rTMS treatment in
general, the current study clearly shows that the second
treatment course reduces tinnitus severity just as well as
the first one. This is in line with former papers which also
reported good response to maintenance treatment [13, 18, 19,
41]. As there are many possibilities as to when, how, and to
whom repeated treatments can be offered, it is not surprising
that past studies and case reports differ a lot regarding the
strategy used for repeated rTMS treatments. In the current
study, we decided to make as little specification of those
variables as possible. This was done in order to be able to get
an overall impression of repeated courses of rTMS for tinnitus
patients and to find out which variables are of more or less
importance for future studies. The only parameter that was
determined in this study was the number of sessions: patients
were treated with the full treatment course of ten sessions of
rTMS. No fixed time schedule was used though but patients
were retreated whenever they requested it. This design has
the advantage that it reflects the typical clinical situation
in which a patient presents for a repeated rTMS treatment.
The correlation between the duration of the intertreatment
interval and the outcome of the second treatment course was
not significant, indicating that it might be not decisive for
treatment response if repeated treatments are applied within
few months after the first treatment attempt or after years.
Similar to the time schedule, the sample of patients
for this study was also not determined beforehand. All
previous studies only considered initial treatment responders
for repeated rTMS courses, preventing the investigation of the
question if the retreatment of a nonresponder is adequate.
The present results show that also nonresponders might
benefit from further rTMS treatment and that the response
to the initial treatment is a good but not a sufficient predictor
for the outcome of the second treatment course. Particularly
if nonresponders experience a deterioration of their tinnitus,
another treatment attempt might be reasonable.
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Figure 3: Treatment outcomes (as measured by TQ differences) resulting from the different treatment protocols.
It turned out that the treatment protocols did not differ
significantly with respect to treatment outcome neither in
the first nor in the second treatment course. This is in line
with past studies indicating that a superiority of combined
protocols as compared with single-site protocols is not
present immediately after rTMS treatment but only after a
certain follow-up period (e.g., [22, 28]). As, in the current
study, treatment outcome was only assessed directly after
the last treatment session but not after a follow-up period, a
difference between protocols was not to be expected.
The explorative character of our study entails limitations
on the conclusions which can be drawn. Neither subjects nor
experimenters were blinded regarding the second treatment
course and the study lacks a wait list or placebo control group.
Furthermore, there was a self-selection bias of patients who
underwent the second rTMS treatment, and also the interval
between the two treatment courses was not standardized.
Therefore it cannot be exactly determined whether the
observed effects are entirely rTMS specific and to which
extent unspecific effects like a tendency to the mean may
have contributed. Furthermore, the protocols used for rTMS
treatment were not kept constant: six different protocols were
used for the first treatment course and four different protocols
for the second treatment course.Nevertheless, the results pro-
vide valuable information for future controlled trials which
are clearly needed to investigate maintenance rTMS in more
detail. In summary, this study demonstrated that (a) repeated
courses of rTMS treatment cause a significant change of
tinnitus severity and (b) the change of tinnitus severity during
the intertreatment interval is a good predictor for treatment
outcome of the second treatment course with patients whose
tinnitus worsens during this interval benefitting most from
the second treatment. It is particularly important to note
that this is also true for initial nonresponders. If a further
deterioration of their tinnitus happens, a repetition of rTMS
treatment might definitely be reasonable in those patients.
5. Conclusions
Presenting a large sample of patients with chronic subjective
tinnitus who were treated with two full courses of rTMS
treatment, the current study shows that the repeated appli-
cation of rTMS is well tolerated and represents a useful
tool in tinnitus management. A second treatment attempt
is especially promising for patients who had experienced
a worsening of their tinnitus during the intertreatment
interval. It is important to note that this relation is also true
for patients who did not respond to the first treatment course:
if those patients present with a deterioration of symptoms,
they might benefit from a second treatment course indeed.
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